Solstice Biologics Raises $18M
San Francisco-based Soltice Biologics said Friday that it has raised $18M in a Series A funding round. The firm, which is developing technology that enables the delivery of RNA-based therapeutics across membranes, said the funding was led by venBio and also included Aeris Capital. The firm's technology is aimed at helping improve the therapeutic potential of RNA interference (RNAi) and microRNA. The firm's technology was licensed from the University of California, San Diego.
posted on Monday, January 7, 2013 (Link to more information)
Related companies:
Solstice
Related stories:
> Solstice Neurosciences Acquired
> Labrys Biologics Raises $31M
> Canaan Partners Raises $675M Fund
> BioMarin Buys Plant From Pfizer
> Unchained Labs Lands $25M
silicontap.com Home